Hepatic NeoplasmsNCT02213692
Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method
An observational study of Hepatic Neoplasms, run by Hui-Chuan Sun at 1 site in China.
Trial summary
Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hepatic Neoplasms
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- May 2014to Oct 2015
- How long will I take part?
- 7 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Genders Eligible for Study: Both Accepts Healthy Volunteers: No
Who may be able to join
- Age ≥18y, and ≤80y;
- No history of liver resection and radiotherapy
- Liver function: Child A with a normal prothrombin time (<13 seconds) and INR (1.15);
- Extent of resection ≥2 segment or diameter of tumor (single nodule) ≥ 8cm or cumulative diameter of tumor (multiple nodule) ≥ 8cm; Eligible patients will be stratified by resection in left lobe or right lobe.
- No tumor thrombosis in main trunk or right and left branch of portal vein or major hepatic vein.
Who cannot join
- Recurrent liver tumor; or simultaneous resection of other organs except gallbladder
- Prothrombin time > 13S;
- Blood platelets count (BPC) < 60x109
- Moderate and severe of esophageal varices detected by CT or MRI
- Diameter of portal vein > 14mm (color ultrasound)
Trial locations and contacts
1 site in 1 country.
China1 site
Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032
About this study
Official title: Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method: A Prospective Randomized Study
Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Technique advances related to liver transection have contributed to reduction in blood loss. Several studies have showed that Harmonic Scalpel in liver resection is safe and easy to use. A nonrandomized study showed use of the Harmonic Scalpel was associated with decreased operative time, blood loss and transfusion requirement, and an increased incidence of postoperative bile leakage. However, no randomized study has compared the difference between liver resection using traditional technology and harmonic Scalpel. The objective of this prospective randomized study is to compare the safety and efficacy of liver resection using the harmonic scalpel device with the "crush-clamp" technique in respect to blood loss, liver transection time, hepatic hilum clamping time, hospital stay and postoperative complications.
Read the detailed description
Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Technique advances related to liver transection have contributed to reduction in blood loss. Several studies have showed that Harmonic Scalpel in liver resection is safe and easy to use. A nonrandomized study showed use of the Harmonic Scalpel was associated with decreased operative time, blood loss and transfusion requirement, and an increased incidence of postoperative bile leakage. However, no randomized study has compared the difference between liver resection using traditional technology and harmonic Scalpel. The objective of this prospective randomized study is to compare the safety and efficacy of liver resection using the harmonic scalpel device with the "crush-clamp" technique in respect to blood loss, liver transection time, hepatic hilum clamping time, hospital stay and postoperative complications. All patients submitted to liver resection are randomized into two groups: those submitted to liver resection with the use of "crush-clamp" technique. (group Α) and those with the use of the Harmonic Scalpel device (group Β).
Crush-clamping Method (group A) :Patients submitted to liver resection with the use of "crush-clamping" technique.
Device: Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
Harmonic Scalpel (group B) :Patients submitted to liver resection with the use of the Harmonic Scalpel device.Device: liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
Primary Outcome Measures:
Blood loss during operation [an expected average of 3 hours] operation][Designated as safety issue: Yes] Postoperative complications including bile leakage, bleeding, morbidity, injured Liver function [Time Frame: participants will be followed for the duration of hospital stay, an expected average of 8 days] [Designated as safety issue: Yes]
Secondary Outcome Measures:
Transection time from Mark of the cutting edge to finish disposed of the cutting edge [Designated as safety issue: No] Hepatic hilar clamping time (Pringle's method) [the duration of clamping of hepatic hilar] [Designated as safety issue: No] Hospital stay [participants will be followed for the duration of hospital stay, an expected average of 8 days] [Designated as safety issue: No] Enrollment: 128 Study Start Date: June 2014 Study Completion Date: May 2015 Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Eligibility:
Genders Eligible for Study: Both Accepts Healthy Volunteers: No
Criteria:
Inclusion Criteria:
- Age ≥18y, and ≤80y;
- No history of liver resection and radiotherapy
- Liver function: Child A with a normal prothrombin time (<13 seconds) and international normalized ratio (INR )(<1.15);
- Extent of resection ≥2 segment or diameter of tumor (single nodule) ≥ 8cm or cumulative diameter of tumor (multiple nodule) ≥ 8cm; Eligible patients will be stratified by resection in left lobe or right lobe.
- No tumor thrombosis in main trunk or right and left branch of portal vein or major hepatic vein.
Exclusion Criteria:
- Recurrent liver tumor; or simultaneous resection of other organs except gallbladder
- Prothrombin time > 13seconds;
- Blood platelets count (BPC) < 60*109
- Moderate and severe of esophageal varices detected by CT or MRI
- Diameter of portal vein > 14mm (color ultrasound)
- Conditions
- Hepatic Neoplasms
- Keywords
- Liver Resection, Harmonic Scalpel, Crush-clamping, A Prospective Randomized Study
- Medical subject headings
- Liver Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Crush-clamping Method (group A) | Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips. | |
| Harmonic Scalpel Method (group B) | Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood loss
Amount of blood loss will be assayed during operation.
Measured: intraoperatively operation(an average of 3 hours)
Secondary outcomes (4)
Transection time
Liver transection time from Mark of the cutting edge to finish disposed of the cutting edge will be recorded.
Measured: from Mark of the cutting edge to finish disposed of the cutting edge (an average of 1 hour)
Hepatic hilar clamping time
Hepatic hilar clamping time (Pringle's method) will be recorded.
Measured: duration of clamping of hepatic hilar (an average of 30 minutes)
Hospital stay
Time of hospital stay will be recorded.
Measured: dates from admission to discharge (an average of 8 days)
Postoperative complications
Postoperative complications including bile leakage, bleeding, morbidity, injured Liver function will be recorded.
Measured: within 7 days after operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2014 (estimated)
- Study startMay 2014
- Primary completionOct 2015
- Study completionOct 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatic NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 120 participants (actual)
- Target duration
- 7 Days
Sponsor and investigators
- Lead sponsor
- Hui-Chuan Sun
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Hui-Chuan Sun, Fudan University
- Investigators
- Hui Chuan Sun, Professor, Study chair, Fudan UniversityJia Fan, Professor, Principal investigator, Fudan UniversityJian Zhou, Professor, Principal investigator, Fudan UniversityShuang Jian Qiu, Professor, Principal investigator, Fudan UniversityGuo Ming Shi, Asso. Prof., Principal investigator, Fudan UniversityQing Hai Ye, Professor, Principal investigator, Fudan UniversityLu Wang, Professor, Principal investigator, Fudan UniversityXiao Wu Huang, Professor, Principal investigator, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02213692
- Sponsor's protocol ID
- D2014-051
- Status last verified
- Feb 2016
- First submitted
- 30 May 2014
- Last updated
- 4 Feb 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method: A Prospective Randomized Study
- ClinicalTrials.gov ID
- NCT02213692
- Acronym / sponsor ID
- D2014-051
- Conditions
- Hepatic Neoplasms
- Keywords
- Liver Resection, Harmonic Scalpel, Crush-clamping, A Prospective Randomized Study
- Study type
- Observational
- Recruitment status
- Terminated
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Hui-Chuan SunUniversity, hospital or other
- Study start
- May 2014
- Primary completion
- Oct 2015 (actual)
- Study completion
- Oct 2015 (actual)
- First posted
- 11 Aug 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Technique advances related to liver transection have contributed to reduction in blood loss. Several studies have showed that Harmonic Scalpel in liver resection is safe and easy to use. A nonrandomized study showed use of the Harmonic Scalpel was associated with decreased operative time, blood loss and transfusion requirement, and an increased incidence of postoperative bile leakage. However, no randomized study has compared the difference between liver resection using traditional technology and harmonic Scalpel. The objective of this prospective randomized study is to compare the safety and efficacy of liver resection using the harmonic scalpel device with the "crush-clamp" technique in respect to blood loss, liver transection time, hepatic hilum clamping time, hospital stay and postoperative complications.
Detailed description
Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Technique advances related to liver transection have contributed to reduction in blood loss. Several studies have showed that Harmonic Scalpel in liver resection is safe and easy to use. A nonrandomized study showed use of the Harmonic Scalpel was associated with decreased operative time, blood loss and transfusion requirement, and an increased incidence of postoperative bile leakage. However, no randomized study has compared the difference between liver resection using traditional technology and harmonic Scalpel. The objective of this prospective randomized study is to compare the safety and efficacy of liver resection using the harmonic scalpel device with the "crush-clamp" technique in respect to blood loss, liver transection time, hepatic hilum clamping time, hospital stay and postoperative complications. All patients submitted to liver resection are randomized into two groups: those submitted to liver resection with the use of "crush-clamp" technique. (group Α) and those with the use of the Harmonic Scalpel device (group Β).
Crush-clamping Method (group A) :Patients submitted to liver resection with the use of "crush-clamping" technique.
Device: Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
Harmonic Scalpel (group B) :Patients submitted to liver resection with the use of the Harmonic Scalpel device.Device: liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
Primary Outcome Measures:
Blood loss during operation [an expected average of 3 hours] operation][Designated as safety issue: Yes] Postoperative complications including bile leakage, bleeding, morbidity, injured Liver function [Time Frame: participants will be followed for the duration of hospital stay, an expected average of 8 days] [Designated as safety issue: Yes]
Secondary Outcome Measures:
Transection time from Mark of the cutting edge to finish disposed of the cutting edge [Designated as safety issue: No] Hepatic hilar clamping time (Pringle's method) [the duration of clamping of hepatic hilar] [Designated as safety issue: No] Hospital stay [participants will be followed for the duration of hospital stay, an expected average of 8 days] [Designated as safety issue: No] Enrollment: 128 Study Start Date: June 2014 Study Completion Date: May 2015 Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Eligibility:
Genders Eligible for Study: Both Accepts Healthy Volunteers: No
Criteria:
Inclusion Criteria:
- Age ≥18y, and ≤80y;
- No history of liver resection and radiotherapy
- Liver function: Child A with a normal prothrombin time (<13 seconds) and international normalized ratio (INR )(<1.15);
- Extent of resection ≥2 segment or diameter of tumor (single nodule) ≥ 8cm or cumulative diameter of tumor (multiple nodule) ≥ 8cm; Eligible patients will be stratified by resection in left lobe or right lobe.
- No tumor thrombosis in main trunk or right and left branch of portal vein or major hepatic vein.
Exclusion Criteria:
- Recurrent liver tumor; or simultaneous resection of other organs except gallbladder
- Prothrombin time > 13seconds;
- Blood platelets count (BPC) < 60*109
- Moderate and severe of esophageal varices detected by CT or MRI
- Diameter of portal vein > 14mm (color ultrasound)
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 7 Days
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Crush-clamping Method (group A) | – | –Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips. |
| Harmonic Scalpel Method (group B) | – | –Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Genders Eligible for Study: Both Accepts Healthy Volunteers: No
Key inclusion criteria (5 listed)
- Age ≥18y, and ≤80y;
- No history of liver resection and radiotherapy
- Liver function: Child A with a normal prothrombin time (<13 seconds) and INR (1.15);
- Extent of resection ≥2 segment or diameter of tumor (single nodule) ≥ 8cm or cumulative diameter of tumor (multiple nodule) ≥ 8cm; Eligible patients will be stratified by resection in left lobe or right lobe.
- No tumor thrombosis in main trunk or right and left branch of portal vein or major hepatic vein.
Key exclusion criteria (5 listed)
- Recurrent liver tumor; or simultaneous resection of other organs except gallbladder
- Prothrombin time > 13S;
- Blood platelets count (BPC) < 60x109
- Moderate and severe of esophageal varices detected by CT or MRI
- Diameter of portal vein > 14mm (color ultrasound)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Blood loss
Time frame: intraoperatively operation(an average of 3 hours)
Amount of blood loss will be assayed during operation.
4 secondary outcomes
Transection time
Time frame: from Mark of the cutting edge to finish disposed of the cutting edge (an average of 1 hour)
Hepatic hilar clamping time
Time frame: duration of clamping of hepatic hilar (an average of 30 minutes)
Hospital stay
Time frame: dates from admission to discharge (an average of 8 days)
Postoperative complications
Time frame: within 7 days after operation
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2016.
Related trials for Hepatic Neoplasms
Active, not recruitingPhase 2
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers
Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer
RecruitingPhase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Solid Tumors
RecruitingObservational study
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Neoplasms, Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hui Chuan Sun, Professor study chair
Fudan University
Jia Fan, Professor principal investigator
Fudan University
Jian Zhou, Professor principal investigator
Fudan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatic Neoplasms, run by Hui-Chuan Sun at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 4 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood loss (time frame: intraoperatively operation(an average of 3 hours)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2016.